These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

468 related items for PubMed ID: 27535349

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Use of prestudy heparin did not influence the efficacy and safety of rivaroxaban in patients treated for symptomatic venous thromboem-bolism in the EINSTEIN DVT and EINSTEIN PE studies.
    Prandoni P, Prins MH, Cohen AT, Müller K, Pap ÁF, Tewes MC, Lensing AW.
    Acad Emerg Med; 2015 Feb; 22(2):142-9. PubMed ID: 25676529
    [Abstract] [Full Text] [Related]

  • 3. Oral rivaroxaban versus enoxaparin with vitamin K antagonist for the treatment of symptomatic venous thromboembolism in patients with cancer (EINSTEIN-DVT and EINSTEIN-PE): a pooled subgroup analysis of two randomised controlled trials.
    Prins MH, Lensing AW, Brighton TA, Lyons RM, Rehm J, Trajanovic M, Davidson BL, Beyer-Westendorf J, Pap ÁF, Berkowitz SD, Cohen AT, Kovacs MJ, Wells PS, Prandoni P.
    Lancet Haematol; 2014 Oct; 1(1):e37-46. PubMed ID: 27030066
    [Abstract] [Full Text] [Related]

  • 4. Length of stay and economic consequences with rivaroxaban vs enoxaparin/vitamin K antagonist in patients with DVT and PE: findings from the North American EINSTEIN clinical trial program.
    Bookhart BK, Haskell L, Bamber L, Wang M, Schein J, Mody SH.
    J Med Econ; 2014 Oct; 17(10):691-5. PubMed ID: 25065536
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
    Coleman CI, Bunz TJ, Turpie AGG.
    Thromb Haemost; 2017 Oct 05; 117(10):1841-1847. PubMed ID: 28640322
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Cost-effectiveness of rivaroxaban compared with enoxaparin plus a vitamin K antagonist for the treatment of venous thromboembolism.
    Lefebvre P, Coleman CI, Bookhart BK, Wang ST, Mody SH, Tran KN, Zhuo DY, Huynh L, Nutescu EA.
    J Med Econ; 2014 Jan 05; 17(1):52-64. PubMed ID: 24156243
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Bodyweight-adjusted rivaroxaban for children with venous thromboembolism (EINSTEIN-Jr): results from three multicentre, single-arm, phase 2 studies.
    Monagle P, Lensing AWA, Thelen K, Martinelli I, Male C, Santamaría A, Samochatova E, Kumar R, Holzhauer S, Saracco P, Simioni P, Robertson J, Grangl G, Halton J, Connor P, Young G, Molinari AC, Nowak-Göttl U, Kenet G, Kapsa S, Willmann S, Pap AF, Becka M, Twomey T, Beyer-Westendorf J, Prins MH, Kubitza D, EINSTEIN-Jr Phase 2 Investigators.
    Lancet Haematol; 2019 Oct 05; 6(10):e500-e509. PubMed ID: 31420317
    [Abstract] [Full Text] [Related]

  • 10. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.
    Bauersachs RM, Lensing AW, Prins MH, Kubitza D, Pap ÁF, Decousus H, Beyer-Westendorf J, Prandoni P.
    Thromb J; 2014 Oct 05; 12():25. PubMed ID: 25750589
    [Abstract] [Full Text] [Related]

  • 11. Effectiveness and Safety of Non-vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation and Venous Thromboembolism: A Systematic Review and Meta-analyses.
    Almutairi AR, Zhou L, Gellad WF, Lee JK, Slack MK, Martin JR, Lo-Ciganic WH.
    Clin Ther; 2017 Jul 05; 39(7):1456-1478.e36. PubMed ID: 28668628
    [Abstract] [Full Text] [Related]

  • 12. The economic implications of switching to rivaroxaban from enoxaparin plus vitamin K antagonist in the treatment of venous thromboembolism.
    Patel AA, Ogden K, Mody SH, Bookhart B.
    J Med Econ; 2015 May 05; 18(5):323-32. PubMed ID: 25557176
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Reduction in the length of stay with rivaroxaban as a single-drug regimen for the treatment of deep vein thrombosis and pulmonary embolism.
    van Bellen B, Bamber L, Correa de Carvalho F, Prins M, Wang M, Lensing AW.
    Curr Med Res Opin; 2014 May 05; 30(5):829-37. PubMed ID: 24432872
    [Abstract] [Full Text] [Related]

  • 17. The use of rivaroxaban for short- and long-term treatment of venous thromboembolism.
    Cohen AT, Dobromirski M.
    Thromb Haemost; 2012 Jun 05; 107(6):1035-43. PubMed ID: 22371186
    [Abstract] [Full Text] [Related]

  • 18. XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
    Kreutz R, Mantovani LG, Haas S, Monje D, Schneider J, Bugge JP, Gebel M, Tamm M, Ageno W, Turpie AGG.
    Thromb Res; 2019 Apr 05; 176():125-132. PubMed ID: 30825694
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Risk of major bleeding in patients with venous thromboembolism treated with rivaroxaban or with heparin and vitamin K antagonists.
    Di Nisio M, Ageno W, Rutjes AW, Pap AF, Büller HR.
    Thromb Haemost; 2016 Jan 05; 115(2):424-32. PubMed ID: 26511068
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.